ReviewInternational journal of endocrinology and metabolism2025
Prediabetes in Transition: Insights from the Tehran Lipid and Glucose Study.
Review in International journal of endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Prediabetes (Pre-DM) is an intermediate state between normoglycemia and type 2 diabetes (T2D), encompassing heterogeneous phenotypes, including isolated impaired fasting glucose (iIFG), isolated impaired glucose tolerance (iIGT), and combined iIFG-impaired glucose tolerance (IFG-IGT). This review aimed to synthesize evidence from the Tehran Lipid and Glucose Study (TLGS) on modifiable and non-modifiable determinants of Pre-DM transition. Evidence Acquisition: Relevant TLGS publications were identified through PubMed and Scopus up to September 2025 using keywords including "prediabetes," "impaired fasting glucose," "impaired glucose tolerance," "diabetes," "regression," "progression," "determinants," and "Tehran Lipid and Glucose Study." Eligible studies included prospective analyses of Pre-DM regression and progression. Results: Evidence from the Tehran Lipid and Glucose Study indicates that both non-modifiable and modifiable factors influence the Pre-DM transition. Regression to normoglycemia (NGR) was associated with younger age, lower fasting glucose, higher physical activity, and adherence to healthy diets, whereas progression to T2D was associated with obesity, central adiposity, the combined IFG-IGT phenotype, and unhealthy dietary patterns. Specifically, high adherence to the Alternate Healthy Eating Index (AHEI), higher intakes of low-fat dairy, certain minerals, and coffee facilitate regression to NGR, while Western-style diets increase the risk of progression to T2D. Across the phenotypes, regression to NGR was most likely in individuals with IGT, particularly those with ≥ 5% weight loss and adherence to healthy dietary patterns. Combined IFG-IGT benefited from high adherence to the AHEI. The iIFG phenotype appears particularly susceptible to excessive exposure to nitrate/nitrite, zinc, and diets high in cholesterol, saturated, and trans fats, which may attenuate reversion to NGR and facilitate progression to T2D. Conclusions: Findings from the TLGS cohort show that healthy lifestyle factors favor regression to NGR, whereas obesity and poor dietary habits accelerate progression to T2D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.